Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis.

@article{Tambuwala2015TargetedDO,
  title={Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis.},
  author={Murtaza M Tambuwala and Mario C. Manresa and Eoin P Cummins and Vincenzo Aversa and Ivan S Coulter and Cormac T Taylor},
  journal={Journal of controlled release : official journal of the Controlled Release Society},
  year={2015},
  volume={217},
  pages={221-7}
}
Targeting hypoxia-sensitive pathways has recently been proposed as a new therapeutic approach to the treatment of intestinal inflammation. HIF-hydroxylases are enzymes which confer hypoxic-sensitivity upon the hypoxia-inducible factor (HIF), a major regulator of the adaptive response to hypoxia. Previous studies have shown that systemic (intraperitoneal) administration of hydroxylase inhibitors such as dimethyloxalylglycine (DMOG) is profoundly protective in multiple models of colitis, however… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
7 Citations
20 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Hydroxylases as therapeutic targets in in - fl ammatory bowel disease

  • S. P. Colgan, C. T. Taylor
  • Lab . Investig .
  • 2013

Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor

  • M. L. Hart
  • J. Immunol
  • 2011

Similar Papers

Loading similar papers…